A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683

Summary

A phase 2, multicenter, uncontrolled, open-label trial in participants with Multi-drug Resistant Tuberculosis (MDR-TB). Only participants who completed Trial 242-07-204 (NCT00685360) were eligible. The trial was performed globally at 14 sites qualified to treat MDR-TB. All 434 participants who completed Trial 242-07-204 were eligible for this trial if there was still potential clinical benefit to them and all inclusion criteria and no exclusion criteria were met.

Timeline

Start

2009-03-26

Primary completion

2011-10-27

Completion

2011-10-27

Drugs

Indications